- Home
- CMC vs NUVL Comparison
CMC vs NUVL Comparison
Compare CMC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- NUVL
- Stock Information
- Founded
- CMC 1915
- NUVL 2017
- Country
- CMC United States
- NUVL United States
- Employees
- CMC N/A
- NUVL N/A
- Industry
- CMC Steel/Iron Ore
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CMC Industrials
- NUVL Health Care
- Exchange
- CMC Nasdaq
- NUVL Nasdaq
- Market Cap
- CMC 6.3B
- NUVL 6.7B
- IPO Year
- CMC 1987
- NUVL 2021
- Fundamental
- Price
- CMC $51.06
- NUVL $82.06
- Analyst Decision
- CMC Buy
- NUVL Strong Buy
- Analyst Count
- CMC 7
- NUVL 10
- Target Price
- CMC $65.00
- NUVL $112.60
- AVG Volume (30 Days)
- CMC 962.2K
- NUVL 411.4K
- Earning Date
- CMC 01-06-2025
- NUVL 02-25-2025
- Dividend Yield
- CMC 1.41%
- NUVL N/A
- EPS Growth
- CMC N/A
- NUVL N/A
- EPS
- CMC 4.14
- NUVL N/A
- Revenue
- CMC $7,925,972,000.00
- NUVL N/A
- Revenue This Year
- CMC $1.17
- NUVL N/A
- Revenue Next Year
- CMC $9.12
- NUVL N/A
- P/E Ratio
- CMC $12.34
- NUVL N/A
- Revenue Growth
- CMC N/A
- NUVL N/A
- 52 Week Low
- CMC $47.42
- NUVL $61.80
- 52 Week High
- CMC $64.53
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- CMC 31.35
- NUVL 29.27
- Support Level
- CMC $48.43
- NUVL $81.11
- Resistance Level
- CMC $63.49
- NUVL $84.83
- Average True Range (ATR)
- CMC 1.76
- NUVL 3.25
- MACD
- CMC -1.10
- NUVL -0.83
- Stochastic Oscillator
- CMC 17.46
- NUVL 6.21
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has two reportable segments: North America and Europe.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.